SHANGHAI – Hutchinson China Meditech Ltd. (Chi-Med) has struck a new deal with its joint venture partner of 13 years, Shanghai Traditional Chinese Medicine Co. Ltd. (STCM), to exclusively sell six prescription drugs in China. Chi-Med's commercial operations help to fund its extensive R&D efforts, with seven candidates in the clinic for oncology, immunology and inflammation.

SHANGHAI – It is no secret that China is heavy on generics and light on innovation. But what happens when a successful drugmaker with deep pockets and a visionary chairman decides to take on drug discovery? Haiyan Pharmaceutical Technology Co. Ltd., the drug development subsidiary of the Yangtze River Pharmaceutical Group (YRP), and its team of executive returnees are set to prove that innovation can be implanted anywhere, even in a risk adverse generics maker.

SHANGHAI – Hutchison Medipharma Ltd. (HMP) is set to turn a corner announcing strong early results for not one, but three of its oncology drugs at ASCO 2014 this weekend in Chicago. Arguably the most exciting is the phase I data for Volitinib, a c-Met inhibitor that has shown strong results in patients with papillary renal cell carcinoma (PRCC), a rare form of cancer with no existing treatment.

SHANGHAI – Glaxosmithkline plc has confirmed the company is under investigation by the UK Serious Fraud Office (SFO). The case is presumed to be related to the almost year-long corruption investigation into GSK China activities that came to a close last week.

SHANGHAI – At the 5th Annual Biosimilars Asia conference held here, a varied mix of Asian biosimilar developers and the consultants that advise them were on hand to discuss the commercial opportunity for biosimilars, if one can only figure out the numerous and costly challenges first.

SHANGHAI – At the 5th Annual Biosimilars Asia conference held here, a varied mix of Asian biosimilar developers and the consultants that advise them were on hand to discuss the commercial opportunity for biosimilars, if one can only figure out the numerous and costly challenges first.

SHANGHAI – Neostem Inc. signed an exclusive license agreement with Cellular Biomedicine Group, of Shanghai, for its patient-specific immunotherapy (DC-TC) to treat late-stage hepatocellular carcinoma (HCC) in China, home to more than 45 percent of the world's HCC patients.

SHANGHAI – In its third academic collaboration deal announced in China this year, Astrazeneca plc, of London, signed a translational research agreement with scientists from Tianjin Medical University (TMU) to explore novel targets for cardiac fibrosis, important in the area of cardiovascular disease (CVD).

SHANGHAI – In a press conference, the Ministry of Public Security (MPS) announced that its 10-month bribery investigation into the China operations of Glaxosmithkline plc had come to a close. The case will be transferred to provincial prosecutors in Changsha to further review the case.